Cationic amphiphilic peptides with cancer-selective toxicity

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cationic amphiphilic peptides (CAPs) have emerged as potential anticancer agents with selective toxicity.
• CAPs exhibit anticancer activity through membranolytic mechanisms, disrupting cancer cell membranes or mitochondria.
• Their mechanism of action, involving electrostatic attraction to negatively charged cell membranes, bypasses common resistance pathways.

Purpose of the Study:

• To review the current understanding of CAPs' anticancer activity and modes of action.
• To discuss the challenges and potential solutions in developing CAP-based chemotherapeutics.
• To highlight the potential of CAPs in overcoming drug resistance in cancer treatment.

Main Methods:

• Review of existing literature on cationic amphiphilic peptides and their anticancer properties.
• Analysis of the mechanisms of action, including membranolytic and non-membranolytic pathways.
• Discussion of challenges in peptide-based drug development, such as pharmacokinetics and manufacturing costs.

Main Results:

• CAPs can be classified into two groups based on their toxicity spectrum: those selectively toxic to cancer cells and those toxic to both cancer and non-cancer cells.
• Membranolysis, targeting cancer cell membranes or mitochondria, is a primary mode of action for many CAPs.
• Non-membranolytic mechanisms are increasingly recognized for their contribution to anticancer effects.

Conclusions:

• CAPs offer a promising strategy for cancer treatment due to their ability to bypass resistance mechanisms.
• Peptidomimetic approaches and targeted delivery systems are key to overcoming pharmacokinetic limitations and improving selectivity.
• Further investigation into CAP mechanisms and development of advanced delivery systems are essential for clinical translation.